Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: A Prospective, Multicenter, Open-Label, Randomized Controlled Phase III Study

NCT06925243 is registered in ClinicalTrials.gov with Zuoyi Jiao as lead sponsor.

NCT NCT06925243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06925243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: A Prospective, Multicenter, Open-Label, Randomized Controlled Phase III Study
Lead sponsor
Zuoyi Jiao
Phase
Phase 3
Overall status
Recruiting
Start date
April 15, 2025
Completion date
December 31, 2030
Enrollment
682 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant chemotherapy, gastric cancer (including stomach and gastroesophageal junction [gej]), mpr, neoadjuvant therapy, orr,os,pfs, pcr rate